Medtronic PLC $MDT Stock Position Lowered by Montag A & Associates Inc.

Montag A & Associates Inc. decreased its position in Medtronic PLC (NYSE:MDT) by 9.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 7,244 shares of the medical technology company’s stock after selling 761 shares during the period. Montag A & Associates Inc.’s holdings in Medtronic were worth $637,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in MDT. Brighton Jones LLC boosted its position in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the period. Schechter Investment Advisors LLC lifted its position in shares of Medtronic by 58.8% in the first quarter. Schechter Investment Advisors LLC now owns 11,024 shares of the medical technology company’s stock worth $991,000 after purchasing an additional 4,082 shares in the last quarter. Florida Financial Advisors LLC purchased a new stake in shares of Medtronic in the first quarter worth approximately $229,000. Edgestream Partners L.P. acquired a new stake in shares of Medtronic during the first quarter worth approximately $325,000. Finally, Signaturefd LLC grew its position in Medtronic by 14.3% during the first quarter. Signaturefd LLC now owns 14,325 shares of the medical technology company’s stock valued at $1,287,000 after purchasing an additional 1,797 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDT has been the subject of a number of research analyst reports. Wells Fargo & Company increased their target price on shares of Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Daiwa Capital Markets increased their price objective on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Truist Financial lifted their price objective on Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. Mizuho boosted their target price on Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $98.00 price target on shares of Medtronic in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

Insiders Place Their Bets

In other news, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.26% of the stock is currently owned by insiders.

Medtronic Price Performance

Shares of NYSE:MDT opened at $95.32 on Wednesday. The stock has a market capitalization of $122.27 billion, a P/E ratio of 26.26, a P/E/G ratio of 2.42 and a beta of 0.77. The business has a 50-day moving average of $94.24 and a two-hundred day moving average of $90.18. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $99.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same period last year, the business earned $1.23 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.